海辰药业：“阿昔莫司胶囊”取得药品注册证书

Group 1 - The core point of the article is that Haichen Pharmaceutical has received approval from the National Medical Products Administration for its product "Aximol" capsules [1] - Haichen Pharmaceutical's revenue composition for the year 2024 is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [2] - As of the latest report, Haichen Pharmaceutical has a market capitalization of 6.4 billion yuan [3] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a robust market for biopharmaceuticals [3] - There is a contrast noted between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [3]